Ropes & Gray advised Ginkgo Bioworks, a horizontal platform for cell programming, in an agreement to acquire biotechnology company Zymergen in an all-stock transaction that values Zymergen at approximately $300 million.
Under the agreement, which has been unanimously approved by the board of directors of both companies, Zymergen stockholders will receive a fixed exchange ratio of 0.9179 Ginkgo shares for each Zymergen share, representing a 5.25% pro forma ownership of Ginkgo following the transaction that was announced on July 25.
The Ropes & Gray team was led by mergers & acquisitions partner Suni Sreepada, mergers & acquisitions associate Kate Fisher and mergers & acquisitions partner Marko Zatylny and included IP transactions partner Amanda Austin, employment & benefits partners Renata Ferrari, Richard Kidd and Megan Bisk, tax partner Pam Glazier, litigation & enforcement partners Lisa Bebchick, Mike McFalls, Martin Crisp, Ama Adams and Ruchit Patel, life sciences regulatory & compliance partner Kellie Combs, real estate partner Peter Alpert, data, privacy & cybersecurity partner Ed McNicholas, IP transactions partner Melissa Rones, business restructuring partner Andrew Devore, private equity partner Milap Patel, health care counsel Leslie Thornton, life sciences regulatory & compliance counsel Beth Weinman, litigation & enforcement counsel Deidre Johnson, Alison McLaughlin and Joseph Rafferty, real estate counsel Laurie Nelson and private equity counsel James Kaplan.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.